HSBC Holdings’s AstraZeneca AZN Stock Holding History

HSBC Holdings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-60,000	Closed	-$4.21M	–	2538
2018 Q2	$4.21M	Buy	+60,000	New	+$4.32M	0.01%	1195

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HSBC Holdings's AZN Position: Q2 2026 in Review

HSBC Holdings reduced its AstraZeneca (AZN) stake by 12% in Q2 2026, selling an estimated $141K and leaving 5,545 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

HSBC Holdings first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $494M in Q4 2021. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

HSBC Holdings held 5,545 shares of AstraZeneca worth $1.05M as of Q2 2026.
HSBC Holdings sold 752 AstraZeneca shares in Q2 2026, an estimated $141K.
AstraZeneca made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1918 holding.
HSBC Holdings first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
HSBC Holdings's AstraZeneca position peaked at $494M in Q4 2021.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.